Challenges in developing Geroscience trials

Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challen...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolland, Yves, Sierra, Felipe, Ferrucci, Luigi, Barzilai, Nir, De Cabo, Rafael, Mannick, Joan, Oliva, Anthony, Evans, William, Angioni, Davide, De Souto Barreto, Philipe, Raffin, Jeremy, Vellas, Bruno, Kirkland, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439920/
https://www.ncbi.nlm.nih.gov/pubmed/37598227
http://dx.doi.org/10.1038/s41467-023-39786-7
_version_ 1785093058320138240
author Rolland, Yves
Sierra, Felipe
Ferrucci, Luigi
Barzilai, Nir
De Cabo, Rafael
Mannick, Joan
Oliva, Anthony
Evans, William
Angioni, Davide
De Souto Barreto, Philipe
Raffin, Jeremy
Vellas, Bruno
Kirkland, James L.
author_facet Rolland, Yves
Sierra, Felipe
Ferrucci, Luigi
Barzilai, Nir
De Cabo, Rafael
Mannick, Joan
Oliva, Anthony
Evans, William
Angioni, Davide
De Souto Barreto, Philipe
Raffin, Jeremy
Vellas, Bruno
Kirkland, James L.
author_sort Rolland, Yves
collection PubMed
description Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.
format Online
Article
Text
id pubmed-10439920
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104399202023-08-21 Challenges in developing Geroscience trials Rolland, Yves Sierra, Felipe Ferrucci, Luigi Barzilai, Nir De Cabo, Rafael Mannick, Joan Oliva, Anthony Evans, William Angioni, Davide De Souto Barreto, Philipe Raffin, Jeremy Vellas, Bruno Kirkland, James L. Nat Commun Review Article Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience. Nature Publishing Group UK 2023-08-19 /pmc/articles/PMC10439920/ /pubmed/37598227 http://dx.doi.org/10.1038/s41467-023-39786-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Rolland, Yves
Sierra, Felipe
Ferrucci, Luigi
Barzilai, Nir
De Cabo, Rafael
Mannick, Joan
Oliva, Anthony
Evans, William
Angioni, Davide
De Souto Barreto, Philipe
Raffin, Jeremy
Vellas, Bruno
Kirkland, James L.
Challenges in developing Geroscience trials
title Challenges in developing Geroscience trials
title_full Challenges in developing Geroscience trials
title_fullStr Challenges in developing Geroscience trials
title_full_unstemmed Challenges in developing Geroscience trials
title_short Challenges in developing Geroscience trials
title_sort challenges in developing geroscience trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439920/
https://www.ncbi.nlm.nih.gov/pubmed/37598227
http://dx.doi.org/10.1038/s41467-023-39786-7
work_keys_str_mv AT rollandyves challengesindevelopinggerosciencetrials
AT sierrafelipe challengesindevelopinggerosciencetrials
AT ferrucciluigi challengesindevelopinggerosciencetrials
AT barzilainir challengesindevelopinggerosciencetrials
AT decaborafael challengesindevelopinggerosciencetrials
AT mannickjoan challengesindevelopinggerosciencetrials
AT olivaanthony challengesindevelopinggerosciencetrials
AT evanswilliam challengesindevelopinggerosciencetrials
AT angionidavide challengesindevelopinggerosciencetrials
AT desoutobarretophilipe challengesindevelopinggerosciencetrials
AT raffinjeremy challengesindevelopinggerosciencetrials
AT vellasbruno challengesindevelopinggerosciencetrials
AT kirklandjamesl challengesindevelopinggerosciencetrials
AT challengesindevelopinggerosciencetrials

Ejemplares similares